

Presentation for investors, analysts and media

Basel, August 13, 2025



DISCLAIMER

This presentation contains forward-looking statements, including statements regarding the beliefs, expectations and assumptions of future results, performance or achievements of Straumann Group, that are based upon information available to Straumann Group as of the date such statements are made. Forward-looking statements are neither historical facts nor assurances of future performance. They may, but need not, be identified by words such as: "anticipate," "intend," "plan," "goal," "believe," "project," "estimate," "expect," "future," "likely," "may," "should," "will" and similar references to future periods or events. Such forward-looking statements reflect the views, beliefs, assumptions and expectations of Straumann Group or its management at the time the statements are made, and they are subject to known and unknown risks, uncertainties and other factors that may be outside of Straumann Group's control. Such known and unknown risks, uncertainties and other factors underlying forward-looking statements may cause the actual results, performance or achievements of the Group to differ materially from those expressed or implied in this presentation. Accordingly, you should not rely on any forward-looking statements contained in this presentation. Important factors that could cause the Group's expectations regarding future results, performance or achievements to differ materially from those expressed in a forwardlooking statement include, but are not confined to, future global economic conditions, pandemics, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside Straumann Group's control. Should one or more of these risks, uncertainties or other factors materialize or should underlying views, beliefs, assumptions or expectations prove incorrect, actual outcomes may vary materially from those forecasted or expected. Straumann Group is providing the information in this presentation as of the date it is given and does not undertake any obligation to update any statements as a result of new information, future events or otherwise. This presentation constitutes neither an offer to sell nor a solicitation to buy any securities.

AGENDA

Highlights	Guillaume Daniellot
Financials	Isabelle Adelt
Recent achievements & strategy	Guillaume Daniellot
Outlook 2025	Guillaume Daniellot
Q&A	Guillaume Daniellot, Isabelle Adelt



STRONG HALF-YEAR AND SECOND-QUARTER RESULTS

Revenue in H1 2025¹

1.3 bn

CHF 667.5 m revenue in Q2

Organic revenue growth in H1 2025¹

10.2%

or 5.9% in CHF and 9.3% organic growth² in Q2 or 1.9% in CHF EBIT margin at constant currency³

27.3%

Core EBIT margin 26.6% including strong currency headwinds

Innovation

IEXCEL

Targeting new customer acquisitions

Localized production

Shanghai campus

More licenses obtained

Outlook 2025 confirmed⁴

High-single digit organic revenue growth

with 30 to 60 basis points improvement of the core EBIT margin at constant 2024 currency rates

¹ Financials refer to continuous operations


² Organic growth excluding FY and M&A effects

³ At constant 2024 currency rates

⁴ Barring unforeseen events

STRONG GROWTH DESPITE MACROECONOMIC UNCERTAINTIES

ORGANIC REVENUE GROWTH IN THE SECOND QUARTER




GROUP Q2 25 9.3% Q2 24 14.8%



STRONG RESULTS WITH CONSIDERABLE FX HEADWINDS


REVENUE DEVELOPMENT BREAKDOWN (IN CHF MILLION, ROUNDED)



CORE GROSS MARGIN AT 72.1%


GROSS PROFIT MARGIN REMAINS AT A HIGH LEVEL DESPITE GROWTH INVESTMENTS AND US TARIFFS

in %, rounded




CORE EBIT MARGIN REACHED 26.6%

CORE EBIT MARGIN AT CONSTANT 2024 CURRENCY RATES: 27.3%¹



FREE CASH FLOW DEVELOPMENT

IN CHF MILLION, ROUNDED



HALF-YEAR CORE FINANCIALS AT A GLANCE


NET PROFIT ROSE 16% TO 265 MILLION AT CONSTANT CURRENCIES

	HY1 2025 ¹	% of Revenue	CER Change in %2	CER Margin Change ²
REVENUE	1 348		10.2%	
COGS	-376	27.9%		
GROSS PROFIT	972	72.1%	10.3%	+10 bps
Operating expenses	-619	45.9%		
Other Result	5	0.4%		
EBIT	358	26.6%	8.7%	-40 bps
EBIT Margin at 2024 ³		27.3%		-30 bps
Financial result	-24	1.8%		
Associates	-9	0.7%		
Income tax	-60	4.4%		
NET PROFIT (from continuing operations)	266	19.7%	2.6%	-140 bps
Loss from discontinued operations	-1			
NET PROFIT	265	19.7%	15.9%	+100 bps
Basic EPS	1.66			



HUGE OPPORTUNITIES – IN IMPLANTOLOGY AND BEYOND

ADDRESSABLE MARKET GREW FROM CHF 19 BN TO ABOUT CHF 20BN GLOBALLY






CLEAR AND CONSISTENT STRATEGIC ROAD MAP

THREE PILLARS TO CREATE ADDITIONAL CUSTOMER VALUE




IEXCEL – SIMPLIFYING COMPLEXITY IN IMPLANTOLOGY



IEXCEL SLA LAUNCH FOR BROADER POSITIONING

OPTIONS EXPANSION WITH INNOVATIVE MATERIALS AND SURFACES





SLActive advanced surface technology supports osseointegration faster



Roxolid helps reduce invasiveness and treatment complexity



SLA is a proven surface technology that promotes reliable bone integration for standard healing protocols

ACQUISITION OF MAXON DENTAL TO EXPAND CERAMIC IMPLANT CAPABILITIES

- World's first two-piece ceramic implant system using proprietary ceramic injection molding
- Scalable production processes enabling highvolume manufacturing with consistent quality



FAST MOLAR – EFFORTLESS 3-STEP WORKFLOW

THE STREAMLINED SOLUTION FOR IMMEDIATE SINGLE-MOLAR RESTORATION





1 Place Immediate socket seal



2 Scan Without removing



Restore
100% matching emergence profile



STRAUMANN EXACT – A LANDMARK IN DIGITAL DENTISTRY

DIGITAL FULL-ARCH WORKFLOW FROM TEMPORARY TO FINAL RESTORATION



coDiagnostiX

STRAUMANN EXACTTM








CHINA OFFERS MASSIVE GROWTH OPPORTUNITIES

LICENSE IN JUNE FOR LOCAL PRODUCTION - WELL POSITIONED FOR VBP 2.0



OUR CULTURE – THE CATALYST FOR LONG-TERM PERFORMANCE

THE SMILE MOVEMENT





CONFIRMED OUTLOOK 2025

BARRING UNFORESEEN CIRCUMSTANCES

Market environment and assumption

- Uncertain economic environment remains
- Group believes global patient flow should remain stable
- Continue to outgrow market

Revenue and profitability

- Organic revenue growth in the high single-digit percentage range
- With 30 to 60 basis points improvement of the core EBIT margin at constant 2024 currency rates

Growth ambition 2030 confirmed





CALENDAR OF UPCOMING EVENTS

2025	Event	Location
August 14 – 15	Swiss Roadshow	Zurich & Geneva
September 3	Wells Fargo Healthcare Conference	Boston
September 4	Goldman Sachs Medtech Conference	London
September 8	Morgan Stanley Healthcare Conference	New York
September 9 – 10	Canada Roadshow	Toronto & Montreal
September 23	UBS Conference	Wolfsberg
September 25	Bank of America Healthcare Conference	London
September 25	Bank of America Healthcare Conference	London
Sep 30 – Oct 28	Quiet period	
October 29	Third quarter 2025 results	Webcast

HALF-YEAR CORE RESULTS RECONCILIATION

(in CHF 1 000)	IFRS	M&A	Impairments	Restructuring	Legal cases	Associates ¹	CORE
Revenue	1 348 199						1348 199
Cost of goods sold	(379 340)	62		3 124			(376 154)
Gross profit	968 860	62		3 124			972 046
Other income	4 382			419			4 801
Distribution expense	(247 397)	3 099		2 255			(242 043)
Administrative expense	(396 231)	5 550	9 506	1 455	3 000		(376 721)
Operating profit	329 613	8 710	9 506	7 254	3 000		358 082
Finance income	84 207	(7 421)				(687)	76 098
Finance expense	(112 451)	11 955				482	(100 014)
Share of result of associates	(8 866)						(8 866)
Profit before income tax	292 502	13 244	9 506	7 254	3 000	(206)	325 300
Income tax expense	(54 317)	(2 089)	(1 317)	(1 534)	(331)		(59 589)
NET PROFIT FROM CONTINUING OPERATIONS	238 185	11 155	8 189	5 719	2 669	(206)	265 711
Loss from discontinued operations, net of tax	(790)						(790)
NET PROFIT	237 395	11 155	8 189	5 719	2 669	(206)	264 921
Attributable to:							
Shareholders of the parent company	236 443	11 111	8 189	5 719	2 669	(206)	263 925
Non-controlling interests	952	44		» »·			996
Operating profit	329 613	8 710	9 506	7 254	3 000		358 082
Depreciation & amortization	88 634	(8 710)	(9 506)	(16)			70 402
EBITDA	418 247			7 237	3 000		428 485

HALF-YEAR IFRS FINANCIALS AT A GLANCE


NET PROFIT ROSE 14% TO 237 MILLION AT CONSTANT CURRENCIES

	HY1 2025 ¹	% of Revenue	CER Change in %2	CER Margin Change ²
REVENUE	1 348		10.2%	
COGS	-379	28.1%		·
GROSS PROFIT	969	71.9%	10.5%	+20 bps
Operating expenses	-643	47.7%		
Other Result	4	0.3%		
EBIT	330	24.4%	5.9%	-100 bps
Financial result	-28	2.1%		
Associates	-9	0.7%		
Income tax	-54	4.0%		
NET PROFIT (from continuing operations)	238	17.7%	-2.9%	-240 bps
Loss from discontinued operations	-1			
NET PROFIT	237	17.6%	13.5%	+50 bps
Basic EPS	1.49			


CURRENCY EXPOSURE


INCREASING DEPRECIATION OF OTHER CURRENCIES - AMPLIFIED EFFECT FROM THE TARIFF ANNOUNCEMENT

Revenue breakdown H1 2025



Total cost breakdown H1 2025





Average exchange rates (rounded)			Closing	FX sensitivity (+/- 10%) on HY			
		2023	2024	Jun 2025	Jun 2025	Revenue	EBIT
1	EURCHF	0.973	0.951	0.940	0.934	+/- 32m	+/- 18m
1	USDCHF	0.899	0.879	0.863	0.798	+/- 33m	+/- 18m
1	BRLCHF	0.180	0.164	0.149	0.145	+/- 8m	+/-1m
1	CNYCHF	0.127	0.122	0.119	0.111	+/- 22m	+/- 16m

